New Personalized Vaccine May Treat Pancreatic Cancer
A new study published in the journal Nature found that a personalized vaccine, named autogene cevumeran, is showing promising results for treating pancreatic cancer, one of the deadliest malignancies.
Vaccine Shows Promise In Stopping Plaque Buildup in Arteries
Chinese researchers have developed a “cocktail” nanovaccine to prevent plaque from building up in the arteries, an underlying factor in heart disease, which is the leading cause of death worldwide.
Aspirin May Prevent Metastasis of Cancer
Scientists at the University of Cambridge, who have been investigating how certain common medications might hold back the movement of cancer cells, have found that daily low-dose aspirin use could curb the spread of certain cancers, including breast and prostate tumors.
COVID-19 May Increase Kawasaki Disease Risk
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease (KD).
FDA Approves Chikungunya Vaccine
The U.S. Food and Drug Administration (FDA) has approved VIMKUNYA (chikungunya vaccine, recombinant) for injection, the first virus-like particle (VLP) single-dose chikungunya vaccine in the U.S. for persons 12 years of age and older.
GSK’s Penmenvy Meningococcal Vaccine Approved by FDA
GSK’s Penmenvy (meningococcal groups A, B, C, W and Y vaccine) has been approved by the U.S. Food and Drug Administration (FDA) for use in individuals aged 10 through 25 years.
RSV Vaccine Prompts Robust Response in Older Recipients
Findings of a Phase III randomized controlled trial showed Pfizer’s RSV Prefusion F (RSVpreF) vaccine triggered strong immune responses among people aged 60 years and older during its first two seasons.
New Biosimilar Autoimmune Disease Treatment Approved by FDA
Celltrion’s Avtozma (tocilizumab-anoh), a biosimilar to Actemra (tocilizumab), in both intravenous and subcutaneous formulations, has been approved by the U.S. Food and Drug Administration.
FDA Approves New Medication for Acute Pain
The U.S. Food and Drug Administration has approved Vertex Pharmaceutical’s Journavx (suzetrigine), a new type of prescription pain medication for adults to treat moderate to severe acute pain.
Multiple Myeloma Patients Treated with Teclistamab May Benefit from IVIG Supplementation
Results of a recent study show patients with multiple myeloma undergoing teclistamab therapy may benefit from primary intravenous immune globulin supplementation, which appears to reduce the risk of high-grade infection.
